- Home
- Reports Store
- Medical Devices
Coronary Stents Market
Customise your request
Need this report to answer something it does not cover? Tell us the decision you are facing and we will scope the work — or point you to a study that already answers it.
info@cortexmeridian.com+971 56 483 5090Report Scope
| Report ID / SKU | CM-MD-0007 |
|---|---|
| Report Code | CM-MD-P1-1007 |
| Report Type | Market Analysis & Forecast |
| Base Year | 2025 |
| Historical Period | 2021–2025 |
| Forecast Period | 2026–2035 |
| Geographic Scope | Global |
| Global Coverage | Yes |
| Regions Covered | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Countries Covered | US; Canada; Mexico; UK; Germany; France; Italy; Spain; Netherlands; Switzerland; China; India; Japan; South Korea; Australia; Brazil; Argentina; Saudi Arabia; UAE; South Africa (20 countries) |
| Market Size Unit | USD Billion |
| Volume Unit | Stents / PCI Procedures |
| Report Format | PPT / WORD / EXCEL / PDF |
| Page Count | 180-220 |
| Delivery Timeline | 48 hours |
| Sample Available | Yes |
| Author / Analyst | Cortex Meridian Medical Devices Analyst Team |
| Publish Date | October 2026 |
| Last Updated | 2026-10-06 |
Market Overview & Definition

The Coronary Stents market is estimated by Cortex Meridian Research at USD 8.6 billion in 2025 and is forecast to reach approximately USD 11.1 billion by 2035, representing a CAGR of 2.6%. The relatively modest growth rate reflects a mature technology category in which drug-eluting stents are already standard of care in most major markets. Market value is sustained by high PCI procedure volumes, but growth is constrained by pricing pressure, tender competition and limited room for dramatic technology substitution.
The most important opportunities are therefore concentrated in complex PCI and emerging markets. Longer lesions, bifurcations, calcified vessels and large-diameter arteries create demand for improved deliverability and platform performance. In these cases, device differentiation can still command premium pricing and influence physician preference.
Abbott’s XIENCE Skypoint launch in India is a good example of how leading vendors are seeking growth: not by redefining the entire market, but by extending proven drug-eluting technology into broader vessel sizes and more complex procedures while expanding access in high-volume markets. Boston Scientific, Medtronic, Terumo and BIOTRONIK are pursuing similar strategies around platform design, clinical evidence and procedural complexity. The category is therefore commercially important but structurally less dynamic than structural-heart or rhythm-management markets.
Report Description
The Coronary Stents Market covers revenue generated from the defined medical-device products, related consumables and software/services where directly attached to the device workflow. The report excludes unrelated pharmaceuticals and stand-alone healthcare services. The scope is designed for manufacturers, suppliers, distributors, hospitals, diagnostic providers, investors and strategy teams evaluating demand, technology shifts, pricing and competitive opportunity.
Overall Market Dynamics
Drivers
Coronary artery disease burden, PCI utilization, second-generation DES adoption and minimally invasive treatment preference.
Restraints / Risks
Price regulation, commoditization, procedure substitution in selected patients, tender pressure and mature-market saturation.
Opportunities
Next-generation DES, complex-lesion platforms, bioresorbable technologies, emerging-market PCI growth and outpatient intervention.
Strategic themes
AI/connectivity, workflow efficiency, reimbursement, regulatory approvals, recurring consumables/service revenue, and regional access expansion.
Segmentation & Scope
By product: drug-eluting, bare-metal, bioresorbable scaffold; by material/platform; by delivery system; by end use: inpatient, outpatient/ASC, specialty clinics; by region and country.
Regional & Country Outlook

COUNTRY CHAPTER COVERAGE 1. US: market size; procedure volumes; PCI and coronary stents penetration; FDA pipeline; reimbursement; Abbott/Medtronic/Edwards/Boston Scientific competition. 2. Canada: procedure volumes; structural heart; CRM; provincial reimbursement; hospital procurement. 3. UK: NHS cardiology capacity; PCI/TAVR; rhythm management; waiting lists; procurement; reimbursement. 4. Germany: high procedural density; TAVR; EP/CRM; reimbursement; hospital adoption; supplier competition. 5. France: structural heart; interventional cardiology; reimbursement; hospital volumes; device adoption. 6. Italy: PCI/stents demand; regional hospital capacity; reimbursement; procurement. 7. Spain: cardiac procedure volumes; PCI/stents; public hospital procurement; reimbursement. 8. Netherlands: advanced structural-heart and EP adoption; high-value devices; digital monitoring. 9. Switzerland: premium cardiovascular technologies; private/public hospital mix; structural heart; CRM. 10. China: PCI volume; TAVR growth; local device companies; volume-based procurement; pricing; regulatory approvals. 11. India: high CAD burden; PCI; TAVR growth; price caps; domestic manufacturing; hospital expansion. 12. Japan: aging population; TAVR/CRM; reimbursement; domestic and multinational competition. 13. South Korea: advanced cardiac intervention; TAVR/EP; reimbursement; hospital technology adoption. 14. Australia: PCI and coronary stents; reimbursement; cardiac centers; remote monitoring. 15. Brazil: PCI and rhythm management; public/private access; import pricing; hospital concentration. 16. Argentina: cardiology procedures; import dependency; pricing; reimbursement; private hospitals. 17. Saudi Arabia: cardiac center investment; PCI/TAVR; Vision 2030; tenders; localization. 18. UAE: premium cardiology services; structural heart; private hospitals; technology adoption. 19. South Africa: public/private cardiology split; PCI/CRM access; reimbursement; distribution.
Competitive Landscape & Companies Covered
Abbott; Boston Scientific; Medtronic; Terumo; BIOTRONIK; B. Braun; MicroPort; Meril; Biosensors International; Cook Medical
Pricing & Ecosystem
Pricing, Cost & Revenue Intelligence
Pricing intelligence benchmarks capital-system ASPs, disposable/consumable pricing, procedure-linked device pricing, service contracts, software subscriptions and regional tender dynamics where applicable. The model distinguishes capital equipment from recurring revenue and evaluates discounting, bundling, distributor margins, reimbursement sensitivity and premium technology price realization.
Value Chain & Ecosystem Analysis
The ecosystem maps component and sensor suppliers, materials vendors, device OEMs, software/AI partners, contract manufacturers, sterilization and packaging providers, distributors, hospitals/diagnostic laboratories/ASCs, clinicians, payers and regulators. The analysis identifies control points in the value chain, recurring-revenue pools, channel dependencies and partnership opportunities.
Opportunity & White-Space Analysis
A weighted opportunity model scores product segments, technologies, countries, end users and accounts using growth, market size, clinical adoption, reimbursement, competitive intensity, regulatory accessibility and margin potential. Priority white spaces include Next-generation DES, complex-lesion platforms, bioresorbable technologies, emerging-market PCI growth and outpatient intervention.
Executive Summary
Cortex Meridian Research estimates the Coronary Stents market at USD 8.6 billion in 2025, increasing to approximately USD 11.1 billion by 2035 at a CAGR of 2.6%. Growth is modest because DES technology is already widely adopted, but the market remains large due to sustained PCI volumes and continued demand for advanced platforms in complex cases.
Abbott’s XIENCE Skypoint expansion into India highlights the principal growth strategy in this market: extend differentiated stent technology into more complex anatomy and high-volume emerging regions. Competitive advantage will come from deliverability, clinical evidence and procedural performance rather than from a fundamental change in treatment modality.
Key Takeaways
- 2025 Cortex normalized estimate: USD 8.6 billion
- 2035 normalized outlook: USD 11.1 billion
- Normalized 2025–2035 CAGR: 2.6%
- Key growth drivers: Coronary artery disease burden, PCI utilization, second-generation DES adoption and minimally invasive treatment preference.
- Priority opportunity areas: Next-generation DES, complex-lesion platforms, bioresorbable technologies, emerging-market PCI growth and outpatient intervention.
- Primary competitive set: Abbott; Boston Scientific; Medtronic; Terumo; BIOTRONIK; B. Braun; MicroPort; Meril; Biosensors International; Cook Medical
Table of Contents
List of Tables
- Global market value, 2021–2035
- Market by product/device type
- Market by technology
- Market by application/procedure
- Market by end user
- Market by region
- Country market sizing
- Installed base/procedure/test indicators
- ASP/pricing benchmark
- Company/product benchmark
- Opportunity attractiveness scoring
List of Figures
- Market size and CAGR outlook
- Segment attractiveness matrix
- Technology adoption curve
- Regional opportunity heat map
- Competitive positioning matrix
- Value-chain ecosystem map
- Pricing/revenue model
- Opportunity prioritization matrix
Research Methodology
Methodology
Cortex Meridian Research applies a triangulated market-sizing framework combining company disclosures, regulatory databases, procedure/test volumes, installed-base indicators, shipment and utilization data, hospital and laboratory purchasing patterns, reimbursement signals, product approvals, and primary research. Public market benchmarks are used only as external calibration points; Cortex values are normalized to the defined scope and forecast period. Forecasts consider technology adoption, procedure/test growth, replacement cycles, pricing, reimbursement, regulatory changes, and regional healthcare investment.
Data Sources & Validation
Company annual reports and investor materials; FDA, EMA and other regulatory databases; WHO and national health agencies; peer-reviewed clinical literature; procurement and reimbursement sources; hospital/laboratory statistics; trade and shipment indicators; company product portfolios; primary interviews; and public market benchmarks used for calibration.
FAQ — Buyer Questions
Q: What is the 2025 global Coronary Stents market size? A: Cortex Meridian Research estimates it at approximately USD 8.6 billion.
Q: What is the 2035 market outlook? A: The normalized outlook is approximately USD 11.1 billion, based on a 2.6% CAGR assumption.
Q: What are the major growth drivers? A: Coronary artery disease burden, PCI utilization, second-generation DES adoption and minimally invasive treatment preference.
Q: Which opportunities should suppliers prioritize? A: Next-generation DES, complex-lesion platforms, bioresorbable technologies, emerging-market PCI growth and outpatient intervention.
Customization Options
Customization can include country-level sizing, procedure/test volumes, installed base, ASP benchmarking, hospital/lab account mapping, competitor benchmarking, product pipeline analysis, regulatory and reimbursement tracking, KOL mapping, distributor/channel assessment, and opportunity prioritization.
Need something this report does not cover?
Describe the decision you are facing. If a published study already answers it we will point you there; if not, we will scope the work and come back with timeline and cost.
CM-MD-0007 · CM-MD-P1-1007 · 180-220 pages · Published October 2026 · Cortex Meridian Medical Devices Analyst Team
